Comparison of intranasal ciclesonide, oral levocetirizine, and combination treatment for allergic rhinitis

Chang Hoon Kim, Jin Kook Kim, Hyun Jun Kim, Jin Hee Cho, Jung Soo Kim, Yong Dae Kim, Heung Man Lee, Sung Wan Kim, Kyu Sup Cho, Sang Hag Lee, Chae Seo Rhee, Hun Jong Dhong, Ki Sang Rha, Joo Heon Yoon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy and safety of once-daily ciclesonide in comparison to both levocetirizine alone, and a ciclesonide/levocetirizine combination in patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Methods: Subjects exhibiting moderate to severe allergic rhinitis for longer than 1 year were randomized in an open-label, 3-arm, parallel group, multicenter study. Subjects received 200 μg ciclesonide, 5 mg levocetirizine, or a combination of both. Changes from baseline until the end-of-study visit (2 weeks following) were evaluated by reflective total nasal symptom scores (rTNSSs), reflective total ocular symptom scores (rTOSSs), physician-assessed overall nasal signs and symptoms severity (PANS), and rhinoconjunctivitis quality-of-life questionnaires (RQLQ). Results: Significant improvements in rTNSS, PANS, and RQLQ in the ciclesonide monotherapy group were observed in comparison to the levocetirizine alone group. Three individual symptoms of rTNSS, including runny nose, nasal itching, and congestion, were improved in the ciclesonide-treated group. rTOSS scores for ciclesonide monotherapy improved from baseline, but no superiority over levocetirizine was shown. The absolute score and changes in rTNSS and PANS were positively correlated. Ciclesonide spray was more effective than levocetirizine in reducing nasal symptoms in both SAR and PAR patients. Ciclesonide and levocetrizine were well tolerated alone and in combination. Conclusions: Our results provide support for an AR and its Impact on Asthma (ARIA) recommendation stipulating that ciclesonide is superior to levocetirizine for the treatment of AR, with tolerable safety. Addition of levocetirizine to ciclesonide did not give further clinical benefit over monotherapy.

Original languageEnglish
Pages (from-to)158-166
Number of pages9
JournalAllergy, Asthma and Immunology Research
Volume7
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Nose
Rhinitis, Allergic, Perennial
Therapeutics
Seasonal Allergic Rhinitis
Quality of Life
ciclesonide
Allergic Rhinitis
levocetirizine
Safety
Pruritus
Multicenter Studies
Signs and Symptoms
Arm
Asthma
Physicians

Keywords

  • Allergic rhinitis
  • Ciclesonide
  • Levocetirizine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Cite this

Comparison of intranasal ciclesonide, oral levocetirizine, and combination treatment for allergic rhinitis. / Kim, Chang Hoon; Kim, Jin Kook; Kim, Hyun Jun; Cho, Jin Hee; Kim, Jung Soo; Kim, Yong Dae; Lee, Heung Man; Kim, Sung Wan; Cho, Kyu Sup; Lee, Sang Hag; Rhee, Chae Seo; Dhong, Hun Jong; Rha, Ki Sang; Yoon, Joo Heon.

In: Allergy, Asthma and Immunology Research, Vol. 7, No. 2, 2014, p. 158-166.

Research output: Contribution to journalArticle

Kim, CH, Kim, JK, Kim, HJ, Cho, JH, Kim, JS, Kim, YD, Lee, HM, Kim, SW, Cho, KS, Lee, SH, Rhee, CS, Dhong, HJ, Rha, KS & Yoon, JH 2014, 'Comparison of intranasal ciclesonide, oral levocetirizine, and combination treatment for allergic rhinitis', Allergy, Asthma and Immunology Research, vol. 7, no. 2, pp. 158-166. https://doi.org/10.4168/aair.2015.7.2.158
Kim, Chang Hoon ; Kim, Jin Kook ; Kim, Hyun Jun ; Cho, Jin Hee ; Kim, Jung Soo ; Kim, Yong Dae ; Lee, Heung Man ; Kim, Sung Wan ; Cho, Kyu Sup ; Lee, Sang Hag ; Rhee, Chae Seo ; Dhong, Hun Jong ; Rha, Ki Sang ; Yoon, Joo Heon. / Comparison of intranasal ciclesonide, oral levocetirizine, and combination treatment for allergic rhinitis. In: Allergy, Asthma and Immunology Research. 2014 ; Vol. 7, No. 2. pp. 158-166.
@article{c67c59d948064922b7afd7d0128927db,
title = "Comparison of intranasal ciclesonide, oral levocetirizine, and combination treatment for allergic rhinitis",
abstract = "Purpose: To evaluate the efficacy and safety of once-daily ciclesonide in comparison to both levocetirizine alone, and a ciclesonide/levocetirizine combination in patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Methods: Subjects exhibiting moderate to severe allergic rhinitis for longer than 1 year were randomized in an open-label, 3-arm, parallel group, multicenter study. Subjects received 200 μg ciclesonide, 5 mg levocetirizine, or a combination of both. Changes from baseline until the end-of-study visit (2 weeks following) were evaluated by reflective total nasal symptom scores (rTNSSs), reflective total ocular symptom scores (rTOSSs), physician-assessed overall nasal signs and symptoms severity (PANS), and rhinoconjunctivitis quality-of-life questionnaires (RQLQ). Results: Significant improvements in rTNSS, PANS, and RQLQ in the ciclesonide monotherapy group were observed in comparison to the levocetirizine alone group. Three individual symptoms of rTNSS, including runny nose, nasal itching, and congestion, were improved in the ciclesonide-treated group. rTOSS scores for ciclesonide monotherapy improved from baseline, but no superiority over levocetirizine was shown. The absolute score and changes in rTNSS and PANS were positively correlated. Ciclesonide spray was more effective than levocetirizine in reducing nasal symptoms in both SAR and PAR patients. Ciclesonide and levocetrizine were well tolerated alone and in combination. Conclusions: Our results provide support for an AR and its Impact on Asthma (ARIA) recommendation stipulating that ciclesonide is superior to levocetirizine for the treatment of AR, with tolerable safety. Addition of levocetirizine to ciclesonide did not give further clinical benefit over monotherapy.",
keywords = "Allergic rhinitis, Ciclesonide, Levocetirizine",
author = "Kim, {Chang Hoon} and Kim, {Jin Kook} and Kim, {Hyun Jun} and Cho, {Jin Hee} and Kim, {Jung Soo} and Kim, {Yong Dae} and Lee, {Heung Man} and Kim, {Sung Wan} and Cho, {Kyu Sup} and Lee, {Sang Hag} and Rhee, {Chae Seo} and Dhong, {Hun Jong} and Rha, {Ki Sang} and Yoon, {Joo Heon}",
year = "2014",
doi = "10.4168/aair.2015.7.2.158",
language = "English",
volume = "7",
pages = "158--166",
journal = "Allergy, Asthma and Immunology Research",
issn = "2092-7355",
publisher = "Korean Academy of Asthma, Allergy and Clinical Immunology",
number = "2",

}

TY - JOUR

T1 - Comparison of intranasal ciclesonide, oral levocetirizine, and combination treatment for allergic rhinitis

AU - Kim, Chang Hoon

AU - Kim, Jin Kook

AU - Kim, Hyun Jun

AU - Cho, Jin Hee

AU - Kim, Jung Soo

AU - Kim, Yong Dae

AU - Lee, Heung Man

AU - Kim, Sung Wan

AU - Cho, Kyu Sup

AU - Lee, Sang Hag

AU - Rhee, Chae Seo

AU - Dhong, Hun Jong

AU - Rha, Ki Sang

AU - Yoon, Joo Heon

PY - 2014

Y1 - 2014

N2 - Purpose: To evaluate the efficacy and safety of once-daily ciclesonide in comparison to both levocetirizine alone, and a ciclesonide/levocetirizine combination in patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Methods: Subjects exhibiting moderate to severe allergic rhinitis for longer than 1 year were randomized in an open-label, 3-arm, parallel group, multicenter study. Subjects received 200 μg ciclesonide, 5 mg levocetirizine, or a combination of both. Changes from baseline until the end-of-study visit (2 weeks following) were evaluated by reflective total nasal symptom scores (rTNSSs), reflective total ocular symptom scores (rTOSSs), physician-assessed overall nasal signs and symptoms severity (PANS), and rhinoconjunctivitis quality-of-life questionnaires (RQLQ). Results: Significant improvements in rTNSS, PANS, and RQLQ in the ciclesonide monotherapy group were observed in comparison to the levocetirizine alone group. Three individual symptoms of rTNSS, including runny nose, nasal itching, and congestion, were improved in the ciclesonide-treated group. rTOSS scores for ciclesonide monotherapy improved from baseline, but no superiority over levocetirizine was shown. The absolute score and changes in rTNSS and PANS were positively correlated. Ciclesonide spray was more effective than levocetirizine in reducing nasal symptoms in both SAR and PAR patients. Ciclesonide and levocetrizine were well tolerated alone and in combination. Conclusions: Our results provide support for an AR and its Impact on Asthma (ARIA) recommendation stipulating that ciclesonide is superior to levocetirizine for the treatment of AR, with tolerable safety. Addition of levocetirizine to ciclesonide did not give further clinical benefit over monotherapy.

AB - Purpose: To evaluate the efficacy and safety of once-daily ciclesonide in comparison to both levocetirizine alone, and a ciclesonide/levocetirizine combination in patients with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Methods: Subjects exhibiting moderate to severe allergic rhinitis for longer than 1 year were randomized in an open-label, 3-arm, parallel group, multicenter study. Subjects received 200 μg ciclesonide, 5 mg levocetirizine, or a combination of both. Changes from baseline until the end-of-study visit (2 weeks following) were evaluated by reflective total nasal symptom scores (rTNSSs), reflective total ocular symptom scores (rTOSSs), physician-assessed overall nasal signs and symptoms severity (PANS), and rhinoconjunctivitis quality-of-life questionnaires (RQLQ). Results: Significant improvements in rTNSS, PANS, and RQLQ in the ciclesonide monotherapy group were observed in comparison to the levocetirizine alone group. Three individual symptoms of rTNSS, including runny nose, nasal itching, and congestion, were improved in the ciclesonide-treated group. rTOSS scores for ciclesonide monotherapy improved from baseline, but no superiority over levocetirizine was shown. The absolute score and changes in rTNSS and PANS were positively correlated. Ciclesonide spray was more effective than levocetirizine in reducing nasal symptoms in both SAR and PAR patients. Ciclesonide and levocetrizine were well tolerated alone and in combination. Conclusions: Our results provide support for an AR and its Impact on Asthma (ARIA) recommendation stipulating that ciclesonide is superior to levocetirizine for the treatment of AR, with tolerable safety. Addition of levocetirizine to ciclesonide did not give further clinical benefit over monotherapy.

KW - Allergic rhinitis

KW - Ciclesonide

KW - Levocetirizine

UR - http://www.scopus.com/inward/record.url?scp=84937854443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937854443&partnerID=8YFLogxK

U2 - 10.4168/aair.2015.7.2.158

DO - 10.4168/aair.2015.7.2.158

M3 - Article

AN - SCOPUS:84937854443

VL - 7

SP - 158

EP - 166

JO - Allergy, Asthma and Immunology Research

JF - Allergy, Asthma and Immunology Research

SN - 2092-7355

IS - 2

ER -